Ronny Gal, a biopharmaceutical analyst with Bernstein, suggested in a recent report that overall prices for cancer treatments "are likely to decline by 70% in five years" as biosimilar competition enters the fold, according to a Regulatory Affairs Professionals Society report. Amgen and Allergan […]
NPC, Analysis Group Study Focuses on Care Pathways
The National Pharmaceutical Council (NPC) and Analysis Group recently partnered for a study on care pathways, and in it offered several recommendations to address key issues. The study, "U.S. Care Pathways: Continued Focus on Oncology and Outstanding Challenges," looked at "changes in development, […]
FDA to Expand Access to Unapproved Cancer Drugs
The Food and Drug Administration (FDA) is launching a new initiative aimed at bolstering its "expanded access" program, the Washington Post reports. Richard Pazdur, FDA Oncology Center for Excellence director, tells the Post the agency wants to create a clear path for physicians interested in the […]
Panel Discussion to Spotlight Cancer Drugs, Prices
An expert panel is slated the discuss the ongoing balancing act between the price of cancer drugs and the health benefits they bring for patients during the upcoming MedCity CONVERGE conference in Philadelphia, MedCity News reports. The panel, "Value and Cost of Novel Cancer Treatments," is set for […]
Amgen, Syapse Partner for Precision Medicine in Oncology
Amgen and Syapse on Thursday, May 3, announced a new partnership aimed at developing observational research analytics to "assess treatment areas of unmet need in oncology," the American Journal of Managed Care (AJMC) reports. According to the report, the venture will offer Syapse Network members […]
Sweetenham Spotlights Possible Benefits, Problems with RWE in Oncology
John Sweetenham, senior director of clinical affairs and executive medical director of Huntsman Cancer Institute at The University of Utah, in a recent write up takes a look at some of the potential benefits real-world evidence (RWE) has to offer in oncology, as well as some of the possible […]
Article: Value-Based Oncology Care Fails to Address Psychosocial Needs of Patients
A recent article published on Oncology Nursing News suggests conversations about value-based oncology care are ultimately ignoring individual patients, though a growing belief that patient-centric care and shared decision-making are indispensable components in health care delivery. "Part of the […]
Study Finds Success in Value-Based Oncology Model Dependent Upon Type of Cancer Treated
A recent study by Avalere found that an oncology practice's ability to survive in the Oncology Care Model (OCM) can be dependent upon the types of cancers being treated by the practice. According to a Managed Healthcare Executive (MHE) report, the research analyzed care costs and OCM […]
Welch Resigns Amid Plagiarism Dispute
Gilbert Welch, a top health care policy scholar in the U.S., has stepped down from his position at Dartmouth College following an investigation into plagiarism allegations, STAT reports. Dartmouth, according to the report, conducted an internal investigation into the claims that Welch plagiarized […]
Study: Payers Could Save by Cutting Unwarranted Components of Cancer Care
A recent white paper sponsored by NantHealth looks at a recent study which suggests unwarranted components of cancer care racked up an average $25,579 per patient. The multi-year study was conducted in association with researchers from Abramson Cancer Center of the University of Pennsylvania and […]
